Source: International Congress 2014 – Allergy and asthma: novel findings based on human cell biology
Disease area: Airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
D. Sykes, M. Bradley, D. Riddy, L. Willard, E. Powell-Herlaar, D. Sandham, S. Watson, C. Bauer, G. Dubois, S. Charlton (Horsham, West Sussex, United Kingdom; Basel, Switzerland). QAW039, a slowly dissociating CRTh2 antagonist with potential for improved clinical efficacy. Eur Respir J 2014; 44: Suppl. 58, 4074

Member's Comments

No comment yet.

Related content which might interest you: Safety, tolerability and pharmacokinetics of an oral competitive reversible CRTh2 antagonist, QAW039, in healthy subjects Source: International Congress 2014 – Allergy and asthma: novel findings based on human cell biology Year: 2014 Safety, tolerability and pharmacokinetics of QAV680, an oral CRTh2 antagonist, in healthy subjects Source: International Congress 2014 – Allergy and asthma: novel findings based on human cell biology Year: 2014 Characterization QAW039 and QAV680, two novel, potent and selective CRTh2 antagonists Source: International Congress 2014 – Allergy and asthma: novel findings based on human cell biology Year: 2014 ALX-0962, an anti-IgE Nanobody® with a dual mode of action Source: Annual Congress 2013 –Novel drugs for the treatment of asthma and COPD Year: 2013 The in vitro profile of ADC3680, a potent and selective CRTh2 antagonist for the treatment of inadequately controlled asthma Source: Annual Congress 2013 –Novel drugs and biomarkers in respiratory medicine Year: 2013 The inverse agonist propranolol does not confer steroid-sparing activity in persistent asthma Source: International Congress 2014 – Clinical trials of drugs and biomarkers for respiratory diseases Year: 2014 ARRY-502, a potent, selective, oral CRTh2 antagonist reduces Th2 mediators in patients with mild to moderate Th2-driven asthma Source: International Congress 2014 – Novel approaches to human studies in allergy and asthma Year: 2014 The clinical and genetic factors for predicting the response to inhaled corticosteroids Source: International Congress 2014 – Biomarkers of asthma and clinical immunology Year: 2014 Evaluating omalizumab persistency of response after long-term therapy (XPORT) Source: International Congress 2014 – Intervening in allergic asthma Year: 2014 Safety profile and pharmacokinetics of SB010, an inhaled GATA-3-specific DNAzyme, in phase I clinical trials in healthy and asthmatic subjects Source: Annual Congress 2013 –Emerging new targets for the treatment of respiratory diseases Year: 2013 Chronic dosing effects of propranolol in asthma Source: Annual Congress 2013 –Asthma and COPD management: novel clinical findings Year: 2013 Redefining the asthma treatment paradigm using a locally administered dual PI3Kgd inhibitor Source: International Congress 2016 – New therapies and therapeutic targets Year: 2016 Lung specific induction of Wnt-1 has a prophylactic and therapeutic effect on the development of an allergic airway disease Source: Annual Congress 2013 –Murine models of lung immunology Year: 2013 QGE031 (ligelizumab) is more effective than omalizumab and placebo in inhibiting allergen-induced early asthmatic response: Results from a predictive modeling study Source: International Congress 2015 – Asthma mechanisms and management Year: 2015 Optimal technique for measuring the IgE blocked by omalizumab Source: International Congress 2014 – Intervening in allergic asthma Year: 2014 QGE031 high affinity anti-IgE: Tolerability, safety, pharmacokinetics and pharmacodynamics in atopic subjects Source: Annual Congress 2013 –Treatment of asthma Year: 2013 ADEPT-derived, U-BIOPRED validated asthma clinical clusters with Th2 and non-Th2 phenotypes Source: International Congress 2014 – Novel targets and drugs for asthma and COPD Year: 2014 In vitro profile of the new inhaled pan-JAK inhibitor LAS194046 Source: International Congress 2014 – New treatments for cough, asthma, COPD and ILDs Year: 2014 LATE-BREAKING ABSTRACT: Safety, pharmacokinetics and pharmacodynamics of BI 1060469, a novel oral CRTH2 antagonist Source: International Congress 2016 – Asthma management Year: 2016 Efficacy of omalizumab in Polish real-world patients Source: International Congress 2016 – Asthma management Year: 2016